CTOs on the Move

Triosyn Research Inc

www.triosyn.com

 
Triosyn Research Inc is a Mirabel, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.triosyn.com
  • 14163 boul du Curí©-Labelle
    Mirabel, QC CAN J7J 1M3
  • Phone: 450.434.6099

Executives

Name Title Contact Details

Similar Companies

DSM PTG

DSM PTG, Inc is a Berkeley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nova Analytics Corporation

Nova Analytics Corporation is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Morphic Therapeutic

Oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. Morphic Tx is joining a three decade quest led by our scientific founder, Tim Springer, who initially discovered the integrin receptor family in the 1980s. This receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, Crohn`s disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention.

Syreon Corporation

Syreon Corporation is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arvinas

Arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as PROTACs (PROteolysis TArgeting Chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. The proprietary PROTAC-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets.